#USA #Las Vegas #Clinical Trials #VIVA Foundation #TCAR

VIVA 2025 Conference Unveils Pioneering Clinical Trial Results

The VIVA Foundation, a non-profit organization focused on the advancement of vascular medicine, hosted the much-anticipated VIVA 2025 conference in Las Vegas on November 5, 2025, where it showcased groundbreaking results from four important clinical trials. This annual gathering serves as a platform for vascular specialists to share their latest research and insights.

Highlighted Clinical Trials

1. PERFORMANCE III Trial

The PERFORMANCE III trial featured the Neuroguard IEP System, a novel device designed for transcarotid artery revascularization (TCAR). Enrolling 146 high-risk patients across 26 sites, the study's primary focus was on evaluating the 30-day rate of major adverse events (MAE).

Results indicated an impressive MAE rate of only 0.69%, with no recorded strokes or neurological deaths. This showcases the efficacy of dual neuroprotection while streamlining procedural complexity, suggesting potential in improving patient outcomes in vascular interventions.

2. LIFE-BTK Trial

Findings from the LIFE-BTK trial emphasized the long-term effectiveness of the Esprit™ BTK drug-eluting resorbable scaffold. After three years, the trial demonstrated a 33% relative improvement in limb salvage rates, highlighting the scaffold's durability and effectiveness versus traditional methods like percutaneous transluminal angioplasty (PTA). The results advocate for the use of drug-eluting technology in treating chronic limb-threatening ischemia (CLTI).

3. Disrupt PAD BTK II Study

The Disrupt PAD BTK II study focused on patients with calcified below-the-knee lesions treated with intravascular lithotripsy (IVL). A year after treatment, the study revealed a substantial primary patency rate of 67.1% and an outstanding freedom from major amputation rate of 94.8%, demonstrating significant improvements in quality of life for patients suffering from severe peripheral artery disease (PAD).

4. ENGULF Trial

In a groundbreaking study assessing the Hēlo Thrombectomy System, the ENGULF trial examined its efficacy in treating acute submassive pulmonary embolism (PE). With a major adverse event rate of just 0.95%, the study confirmed the safety and effectiveness of this innovative device for rapid treatment.

A Commitment to Advancing Vascular Medicine

The VIVA Foundation is committed to improving education in the field of vascular medicine through these collaborative initiatives. By bringing together experts from various disciplines, the organization is poised to address contemporary challenges faced in vascular care, ensuring better outcomes for patients.

The VIVA 2025 conference not only displayed the latest advancements in clinical research but also emphasized the importance of multidisciplinary approaches in treating complex vascular conditions. As these promising results emerge, they pave the way for innovative therapies that could significantly enhance the quality of life for patients enduring chronic vascular challenges.

For more information about the VIVA Foundation and its commitment to advancing vascular care, visit VIVA Foundation.